You have read all your free articles, to continue reading subscribe to read the rest of this content.
Karolinska Development's portfolio company Aprea is to evaluate its drug candidate for the treatment of ovarian cancer in a new British study. It is a phase 1b/II study on the pharmaceutical project APR-246, reports Life Science Sweden. The drug candidate is part of a new type of potential cancerAlready a…
Lundbeck has announced results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study that assessed the efficacy and tolerability of Vyepti when initiated during a migraine attack in patients who are candidates for preventive therapy. The study met statistical significAlready a subscriber Login You have read all your free articles,…
Genmab announces that daratumumab will be investigated in early stage clinical studies in combination with atezolizumab (anti-PD-L1 antibody), in a solid tumor and multiple myeloma. The studies will be conducted under a clinical trial collaboration agreement between Genmab's licensing partner forAlready a subscriber Login You have read all your free…
Ultimovacs has announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-tAlready a subscriber Login You have read all…
